The EXSCEL Trial: Exenatide's Cardiovascular Evidence
TRIAL-000012
Part of the DietApp.com GLP-1 Trial Database, a comprehensive, regularly reviewed resource.
What It Is
EXSCEL, Exenatide Study of Cardiovascular Event Lowering, evaluated the cardiovascular safety of extended-release exenatide, the active ingredient in the now-discontinued Bydureon BCise brand. It enrolled 14,752 adults with type 2 diabetes, 73% of whom had prior cardiovascular disease, making it one of the larger cardiovascular outcomes trials in the GLP-1 class.
Key Results
EXSCEL demonstrated cardiovascular safety, non-inferiority to placebo, but did not show a statistically significant reduction in major adverse cardiovascular events the way later trials like LEADER, SUSTAIN-6, and REWIND did for their respective medications. A post-hoc analysis found a non-significant 8% reduction in combined heart failure hospitalization and cardiovascular death.
Why This Trial's More Modest Result Matters
EXSCEL is a useful contrast point precisely because its result was less definitive than other GLP-1 cardiovascular trials, it's part of why the cardiovascular benefit seen with medications like liraglutide and semaglutide isn't assumed to be a guaranteed class effect automatically extending to every GLP-1 medication. This is also consistent with real-world data discussed elsewhere in this library, which found exenatide had a comparatively lower rate of certain gastrointestinal adverse events than some other GLP-1 medications, alongside this more modest cardiovascular result.
Current Status
Both exenatide brands, Byetta and Bydureon BCise, were discontinued by AstraZeneca in October 2024, covered in more detail on their respective medication pages.
References
- Holman RR et al., EXSCEL Trial, NEJM
- European Heart Journal: EXSCEL Post-Hoc Analysis of Heart Failure Hospitalization and Cardiovascular Death
Related Resources
Related Articles
How EXSCEL Compares Across the GLP-1 Cardiovascular Trial Landscape
| Trial | Medication | Real Cardiovascular Result |
|---|---|---|
| EXSCEL | Exenatide | Neutral, safe but no significant benefit |
| REWIND | Dulaglutide | Significant real benefit shown |
| LEADER | Liraglutide | Significant real benefit shown |
See DietApp's REWIND and LEADER trial pages for the medications that did show significant benefit. For exenatide's mechanism specifically, see DietApp's how exenatide works explainer.
Frequently Asked Questions
Why did exenatide not show cardiovascular benefit when dulaglutide and liraglutide did? Real, possible factors include population differences and exenatide's shorter-acting profile compared to newer, longer-acting GLP-1 medications.
Is exenatide unsafe because of this neutral result? No, EXSCEL confirmed real, genuine cardiovascular safety, non-inferior to placebo.
Does this affect anyone still using a compounded exenatide product? This is real, relevant safety context worth discussing with your provider, regardless of the specific formulation.
Explore More
Explore the full GLP-1 Tracker knowledge base on DietApp.com
Get Started
Download DietApp.com to track your own progress alongside the evidence behind your treatment.
About DietApp.com
DietApp.com combines evidence-based GLP-1 medication education with practical treatment tracking tools. The information on DietApp.com is intended for educational purposes only and should not replace professional medical advice, diagnosis, or treatment.
Last medically reviewed and updated: July 11, 2026.
exscel-trial-exenatide